(0.500 Kg./1.101 lbs.) Information
showed that a 12-week administration of semaglutide in HFD-induced NAFLD mice reduced body weight, glucose, insulin resistance, LFTs, serum lipids, inflammatory markers [TNF-, interleukin (IL)-6, IL-1], and oxidative stress markers [malonaldehyde (MDA)], thus improving hepatic steatosis, inflammation, mitochondria damage, and fibrosis
Rats treated with 150 and 300 mcg/kg showed an osteoprotective effect by a decrease in trabecular bone percentage by 81.1% and 154.4%, respectively, compared to the osteoporotic group
Liraglutide effects on upper Gastrointestinal investigations: implications prior to bariatric surgery
& Kobayashi, H